Geron (GERN) Current Deferred Revenue (2010 - 2015)
Geron's (GERN) quarterly Current Deferred Revenue came in at $35.0 million in Q2 2015, little changed quarter-over-quarter from $35.0 million in Q1 2015.
Geron (GERN) Current Deferred Revenue (2010 - 2015) Analysis & Trends
Geron has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $35.0 million for Q2 2015.
- Current Deferred Revenue for Q2 2015 came in at $35.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2015 was $35.0 million (changed N/A YoY), and the FY2014 annual result was $35.0 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $35.0 million for Q2 2015 at Geron, roughly flat from $35.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $35.0 million in Q4 2014 to a low of $35.0 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Geron | 729,618.77 | 729,618.77 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 35.00 Mn |
| Mar 31, 2015 | 35.00 Mn |
| Dec 31, 2014 | 35.00 Mn |
| Dec 31, 2010 | 350,000.00 |